Boston Scientific
BSX on NYSE. BSX sells medical devices to hospitals, doctors, and healthcare providers. Market value $62.3bn.
Ranked 20 of 1,305 on tonight’s list. On the list every night since 3 August 2026.
For every $100 of what the whole company costs, it produced $5.87 of spare cash last year. A savings account pays about 4.
You pay 17.8 years of operating profit for the business. The average large US company costs around 18.
The filings do not give us enough to work this out.
Five years of cash, in billions
| Revenue | $7.0bn | $7.1bn | $7.5bn | $8.1bn | $9.1bn |
| Operating margin | -55.6% | 1.7% | -4.0% | -3.5% | 4.9% |
| Debt to equity | n/a | n/a | n/a | n/a | n/a |
| Shares outstanding | 1.45bn | 1.36bn | 1.32bn | 1.33bn | 1.35bn |
Health checks
- Free cash flow positive5 of 5 years
- Accounting looks honest (Beneish)Not enough data
- Financial strength (Piotroski)5 of 9
- Profit backed by cash (accruals)Yes
- Debt0.16× equity
- Revenue growth, five yearsSlow, 6.9% a year
- Buying back its own sharesYes, 7% fewer since 2012
Dates
Funds that own it
| Manager | Value | Change |
|---|---|---|
| Bridgewater Associates | $19m | Added 6× |
| Gotham Asset Management | $16m | Cut 22% |
| Diamond Hill Capital | $7m | Added 5% |
| Glenview Capital | $5m | New position |
| Dodge & Cox | $4m | Held |
| GAMCO Investors | $3m | Cut 58% |
| Aristotle Atlantic Partners | $1m | Cut 89% |
| GMO Asset Management | $930,424 | Added 45% |
| Polen Capital | $202,733 | Cut 99% |
| Lone Pine Capital | $0 | Exited |
From 13F filings for the quarter ending 30 June 2026. These are reported 45 days late and only show long positions.
Insiders
We do not track insider filings for this company yet.
What could go wrong
Cheap for a reason is the question the numbers cannot answer. Whether the price already reflects the risks is what the deep dive is for.
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; the five-year figures are rounded.